Skip to content

NET for SGBV Survivors in Eastern DR Congo

Narrative Exposure Therapy for Survivors of Sexual and Gender Based Violence in Eastern DR Congo

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02989987
Enrollment
201
Registered
2016-12-12
Start date
2016-09-30
Completion date
2019-04-03
Last updated
2019-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posttraumatic Stress Disorder, Shame

Keywords

PTSD, Shame, Narrative Exposure Therapy, Sexual and gender based violence (SGBV), DR Congo

Brief summary

Throughout the last 10 years Narrative Exposure Therapy (NET) has evolved as one of the most effective, culturally sensitive trauma interventions. In the present study the effectiveness of NET delivered by trained health personnel in a sample of survivors of sexual and gender based violence (SGBV) who suffer from Posttraumatic Stress Disorder (PTSD) will be assessed. Structured baseline, 3 and 6 month follow up interviews will be administered to assess the main outcome measures PTSD and shame. The trial will take place in Goma, DR Congo, where SGBV and its sequelae has been a major problem.

Detailed description

Participants will be recruited through local NGOs and eligible clients randomized to the treatment (NET; app. N=100) or treatment-as-usual control (app. N=100) group, respectively. At baseline, 3-month and 6-month post-treatment, sociodemographic data, trauma exposure - esp. SGBV, PTSD, dissociation, shame, functionality and depression will be assessed in a structured interview. The interviews will be conducted by blind Congolese psychological interviewers after an intensive 3-weeks training and continuous supervision.

Interventions

BEHAVIORALNarrative Exposure Therapy
BEHAVIORALSocial Support

A local counselors provides social support on demand.

Sponsors

Vivo international e.V.
CollaboratorINDUSTRY
University of Konstanz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
16 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* SGBV survivors (event happened more than 4 weeks ago) * PTSD diagnosis (DSM-5)

Exclusion criteria

* Acute psychosis * Signs of cerebro-organic disease * Acute drug or alcohol intoxication

Design outcomes

Primary

MeasureTime frameDescription
PSS-I: Posttraumatic Stress Disorder symptom severity (sumscore and diagnosis)Change from baseline to 3 and 6 months post treatmentPTSD Symptom Scale - Interview (PSS-I; Foa & Tolin, 2000)
SVQ: Severity of shame (sumscore)Change from baseline to 3 and 6 months post treatmentShame Variability Questionnaire (Brown, Rizvi & Linehan, unpublished)

Secondary

MeasureTime frameDescription
ShutD: Severity of Shutdown Dissociation Symptoms (sumscore)Change from baseline to 3 and 6 months post treatmentShutdown Dissociation Scale (Schalinski et al., 2015)
PHQ: Depression symptom severity (sumscore)Change in 3 and 6 months post treatmentPatient Health Questionnaire - 9 (PHQ-9; Kroenke & Spitzer, 2002)
Functionality (sumscore)3 and 6 months post treatmentLocal Functionality Index (LFI; Bass et al., 2013)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026